Tixagevimab/AZD8895 represents a distinct treatment approach utilizing paired monoclonal antibodies. Specifically, these medications operate by precisely binding to the spike region of the SARS-CoV-2 pathogen, https://www.targetmol.com/compound/tixagevimab